Streetbeat News

Revenues

IDR

Idaho Strategic Resources (AMEX:IDR) reported Q4 earnings of $0.02 per share, missing the $0.05 estimate, but sales of $3.78M exceeded the $3.70M estimate. This represents a 140% increase in earnings and a 10.05% increase in sales from the same period last year.

Portfolio Pulse from Happy Mohamed

March 25, 2024 | 8:30 pm

VNRX

VolitionRX (AMEX:VNRX) reported Q4 earnings with EPS of $(0.11), meeting analyst estimates, but missed sales forecasts with $243.97K versus the expected $450.00K. Despite the sales miss, this represents a significant increase over the previous year's figures.

Portfolio Pulse from Happy Mohamed

March 25, 2024 | 8:28 pm

BKKT

Bakkt has updated its FY24 outlook, projecting revenues to range between $3,292M and $5,114M, with a significant portion coming from crypto. Operating cash flow usage is expected to decrease by approximately 70% YoY, landing between $58M and $72M. The company anticipates end-of-year cash and equivalents to be between $35M and $50M.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:27 pm

BTCUSD

Thomas Lee, co-founder of Fundstrat Global Advisors, accurately predicted Bitcoin's rise in 2018, suggesting it could reach $150,000 by capturing 1% of global assets. As of 2024, Bitcoin has surpassed $70,000, reflecting its increasing acceptance and role in financial portfolios. Lee's insights will be discussed at Benzinga's Future of Digital Assets conference, highlighting the growing market cap of cryptocurrencies and their appeal as an uncorrelated asset class for diversification.

Portfolio Pulse from Murtuza Merchant

March 25, 2024 | 8:26 pm

REKR

Rekor Systems (NASDAQ:REKR) reported Q4 sales of $11.07M, surpassing the $10.72M estimate, marking a 143.26% increase from $4.55M in the same period last year.

Portfolio Pulse from Happy Mohamed

March 25, 2024 | 8:13 pm

VNRX

VolitionRx Limited (VNRX) reported a significant increase in cash and cash equivalents, totaling approximately $20.7 million as of December 31, 2023, compared to $10.9 million the previous year. The company also saw a 153% increase in revenue, reaching about $775,000 in 2023, and received $13.0 million in milestone payments from Heska Corporation in December 2023. However, net cash used in operating activities was $18.1 million for the year. VolitionRx will host a conference call on March 26, 2024, to discuss these financial highlights and other updates.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:11 pm

EFTR

eFFECTOR Therapeutics reported its financial results for Q4 and the full year of 2023, highlighting a cash position of $18.4M as of December 31, 2023, with expectations to fund operations into Q1 of 2025. The company experienced a decrease in revenue, reporting zero for 2023 compared to $3.6M in 2022, primarily from grant revenue for COVID-19 treatment research. R&D expenses slightly decreased due to lower costs in the zotatifin program, offset by increased expenses in the KICKSTART trial for tomivosertib. G&A expenses also saw a reduction, and the company reported a net loss of $35.8M for the year.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:04 pm

STOK

Stoke Therapeutics (NASDAQ:STOK) reported Q4 earnings with EPS of $(0.60), beating estimates by 4.76% but missing sales estimates with $2.80M against an expected $3.25M. Year-over-year, EPS improved by 7.69% while sales decreased by 14.32%. The company has $201.4M in cash reserves, expected to fund operations until the end of 2025.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:03 pm

BE

Bloom Energy (NYSE:BE) has received mixed analyst ratings over the past three months, with a shift towards more cautious views recently. The average 12-month price target has decreased to $15.38 from $17.00, reflecting a 9.53% drop. Analysts from firms like Morgan Stanley, Piper Sandler, and JP Morgan have adjusted their ratings and price targets, indicating varied expectations for the company's performance. Bloom Energy, known for its solid-oxide fuel cell systems, faces challenges in revenue growth and debt management, despite a strong market capitalization and financial performance indicators such as net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 8:01 pm

APH

Amphenol (NYSE:APH) has been analyzed by 5 financial analysts, showing a range of opinions from bullish to bearish. Recent updates include raised price targets and ratings, with an average 12-month price target of $112.4, marking an 11.01% increase from the previous average of $101.25. The company is a global supplier in connectors and interconnect systems, with strong financial indicators such as a 2.73% revenue growth, a net margin of 15.46%, and an ROE of 6.35%, despite a high debt-to-equity ratio of 0.52.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 7:01 pm